劉麗華++++++蔡君東++++++劉艷琴++++++鄭玉妹++++++王海生++++++丁柏英++++++李曉東++++++劉晶++++++喬煒超++++++董新紅

[摘要] 目的 探討紫杉醇、奈達(dá)鉑同步后程加速超分割放療聯(lián)合體外高頻熱療對局部晚期食管癌的影響。 方法 選取2011年8月～2012年7月承德市腫瘤醫(yī)院收治的局部晚期食管癌患者144例，采用隨機(jī)數(shù)字表法將其分為對照組（72例）與聯(lián)合組（72例）。對照組患者應(yīng)用紫杉醇、奈達(dá)鉑同步后程加速超分割放療干預(yù)，聯(lián)合組患者在對照組放療基礎(chǔ)上聯(lián)合體外高頻熱療，對比兩組患者治療效果及生存率情況，觀察兩組患者毒副作用發(fā)生情況。 結(jié)果 聯(lián)合組患者治療總有效率（86.11%）明顯高于對照組（62.50%），差異有統(tǒng)計(jì)學(xué)意義（P < 0.05）；兩組患者治療期間均存在毒副作用，兩組毒副作用發(fā)生率差異無統(tǒng)計(jì)學(xué)意義（P > 0.05）；聯(lián)合組患者1、2、3、4年生存率（70.83%、55.56%、45.83%、38.89%）明顯高于對照組（55.56%、40.27%、29.17%、22.22%），差異有統(tǒng)計(jì)學(xué)意義（P < 0.05）。 結(jié)論 局部晚期食管癌患者應(yīng)用紫杉醇、奈達(dá)鉑同步后程加速超分割放療聯(lián)合體外高頻熱療治療的效果較好，且生存率高，存在一定推廣價(jià)值。

[關(guān)鍵詞] 奈達(dá)鉑；紫杉醇；后程加速超分割；體外高頻熱療；食管癌

[中圖分類號] R735.1 [文獻(xiàn)標(biāo)識碼] A [文章編號] 1673-7210（2017）08（b）-0080-04

[Abstract] Objective To explore the influence of Paclitaxel and Nedaplatin concurrent late course accelerated hyperfractionated radiotherapy combined with high frequency hyperthermia in vitro on curative effect and survival rate of patients with locally advanced esophageal cancer. Methods From August 2011 to July 2012， in Chengde Tumour Hospital， 144 patients with locally advanced esophageal cancer were selected， and they were divided into control group （72 cases） and observation group （72 cases） according to the random number table method. The control group was treated with Paclitaxel and Nedaplatin concurrent late course accelerated hyperfractionated radiotherapy， and the observation group was given ombined with hyperthermia in vitro on the basis of the control group. The rapeutic effect and survival rate in the two groups were contrasted， and toxic and side effects in the two groups were observed. Results The total effective rate of the combination group （86.11%） was significantly higher than that of the control group （62.50%）， the difference was statistically significant （P < 0.05）. The side effects during the treatment occured in two groups， two groups were compared， the difference was not statistically significant （P > 0.05）. Survival rates of 1， 2， 3， 4 years in the observation group （70.83%， 55.56%， 45.83%， 38.89%） were significantly higher than those in the control group （55.56%， 40.27%， 29.17%， 22.22%）， the differences were statistically significant （P < 0.05）. Conclusion The effect is better of Paclitaxel and Nedaplatin concurrent late course accelerated hyperfractionated radiotherapy combined with hyperthermia in vitro on patients with locally advanced esophageal cancer， with high survival rate. It has a certain promotion value.

[Key words] Nedaplatin； Paclitaxel； Accelerated hyperfractionation； Extracorporeal high-frequency hyperthermia； Esophageal cancerendprint